These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 37544825

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination.
    Grant LR, Slack MPE, Theilacker C, Vojicic J, Dion S, Reinert RR, Jodar L, Gessner BD.
    Clin Infect Dis; 2023 Feb 08; 76(3):e1062-e1070. PubMed ID: 35789262
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB, Major M, Gabriela Grajales A, Nepal RM, Cane A, Gessner B, Vojicic J, Suaya JA.
    Vaccine; 2021 May 21; 39(22):3007-3017. PubMed ID: 33824041
    [Abstract] [Full Text] [Related]

  • 5. Invasive pneumococcal disease among the elderly in the later era of paediatric pneumococcal conjugate vaccination-A longitudinal study over 10 years based on public surveillance data in the Nordics.
    Palmborg A, Skovdal M, Molden T, Åhman H, Chen L, Banefelt J.
    PLoS One; 2023 May 21; 18(6):e0287378. PubMed ID: 37363884
    [Abstract] [Full Text] [Related]

  • 6. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
    Ryman J, Sachs JR, Yee KL, Banniettis N, Weaver J, Weiss T.
    Expert Rev Vaccines; 2024 May 21; 23(1):60-68. PubMed ID: 38073483
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
    Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, Mereckiene J, Knol M, Winje BA, Ciruela P, de Miguel S, Guevara M, MacDonald L, Kozakova J, Slotved HC, Fry NK, Pekka Nuorti J, Danis K, Corcoran M, van der Ende A, Vestrheim DF, Munoz-Almagro C, Sanz JC, Castilla J, Smith A, Colzani E, Pastore Celentano L, Hanquet G, SpIDnet VE study group.
    Vaccine; 2022 Jun 23; 40(29):3963-3974. PubMed ID: 35637067
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Huang L, Wasserman M, Grant L, Farkouh R, Snow V, Arguedas A, Chilson E, Sato R, Perdrizet J.
    Vaccine; 2022 Aug 05; 40(33):4700-4708. PubMed ID: 35753839
    [Abstract] [Full Text] [Related]

  • 10. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis.
    Balsells E, Guillot L, Nair H, Kyaw MH.
    PLoS One; 2017 Aug 05; 12(5):e0177113. PubMed ID: 28486544
    [Abstract] [Full Text] [Related]

  • 11. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M, Christopoulou D, Schmitt HJ.
    BMC Infect Dis; 2015 Oct 14; 15():419. PubMed ID: 26468008
    [Abstract] [Full Text] [Related]

  • 12. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P.
    Clin Infect Dis; 2017 Jan 15; 64(2):175-183. PubMed ID: 27986682
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era.
    de Miguel S, Domenech M, González-Camacho F, Sempere J, Vicioso D, Sanz JC, Comas LG, Ardanuy C, Fenoll A, Yuste J.
    Clin Infect Dis; 2021 Dec 06; 73(11):e3778-e3787. PubMed ID: 32990303
    [Abstract] [Full Text] [Related]

  • 15. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.
    Mungall BA, Hoet B, Nieto Guevara J, Soumahoro L.
    Expert Rev Vaccines; 2022 Feb 06; 21(2):201-214. PubMed ID: 34882050
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N, Kent A, Amin-Chowdhury Z, Sheppard C, Fry N, Ramsay M, Ladhani SN.
    Vaccine; 2019 Jul 26; 37(32):4491-4498. PubMed ID: 31272872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.